Drug intelligence / Profile preview

Erbai decoction

Development stage: Preclinical
Administration: Oral

Overview

Erbai decoction (二白饮) is a Traditional Chinese Medicine (TCM) formula that has been investigated for its potential therapeutic effects in Parkinson's disease (PD). Preclinical studies in PD rat models suggest that Erbai decoction can alleviate injury to the substantia nigra pars compacta (SNpc) by activating mitophagy. Its mechanism of action is believed to involve the regulation of the p38 MAPK/Parkin signaling pathway. The decoction is a complex mixture, with studies identifying numerous unique components in its serum.

Other names: 二白饮

Targets

PRKN (E3 ubiquitin-protein ligase parkin)RK (Ribokinase)

Beyond the preview

Go deeper on Erbai decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Erbai decoction.

Explore the full profile